Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PRKACA_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PRKACA_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PRKACA_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PRKACA_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PRKACA_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00162361 | Colorectum | SER | macroautophagy | 79/2897 | 291/18723 | 1.97e-07 | 1.10e-05 | 79 |
GO:00323881 | Colorectum | SER | positive regulation of intracellular transport | 59/2897 | 202/18723 | 4.98e-07 | 2.48e-05 | 59 |
GO:00070431 | Colorectum | SER | cell-cell junction assembly | 45/2897 | 146/18723 | 2.23e-06 | 9.31e-05 | 45 |
GO:00069131 | Colorectum | SER | nucleocytoplasmic transport | 77/2897 | 301/18723 | 3.39e-06 | 1.32e-04 | 77 |
GO:00511691 | Colorectum | SER | nuclear transport | 77/2897 | 301/18723 | 3.39e-06 | 1.32e-04 | 77 |
GO:00343291 | Colorectum | SER | cell junction assembly | 100/2897 | 420/18723 | 4.23e-06 | 1.61e-04 | 100 |
GO:00433931 | Colorectum | SER | regulation of protein binding | 54/2897 | 196/18723 | 1.00e-05 | 3.31e-04 | 54 |
GO:00467771 | Colorectum | SER | protein autophosphorylation | 60/2897 | 227/18723 | 1.36e-05 | 4.25e-04 | 60 |
GO:00468221 | Colorectum | SER | regulation of nucleocytoplasmic transport | 34/2897 | 106/18723 | 1.46e-05 | 4.47e-04 | 34 |
GO:00516041 | Colorectum | SER | protein maturation | 73/2897 | 294/18723 | 1.82e-05 | 5.38e-04 | 73 |
GO:00066111 | Colorectum | SER | protein export from nucleus | 22/2897 | 57/18723 | 1.91e-05 | 5.58e-04 | 22 |
GO:00432971 | Colorectum | SER | apical junction assembly | 27/2897 | 78/18723 | 2.36e-05 | 6.64e-04 | 27 |
GO:00468241 | Colorectum | SER | positive regulation of nucleocytoplasmic transport | 23/2897 | 62/18723 | 2.64e-05 | 7.21e-04 | 23 |
GO:01201931 | Colorectum | SER | tight junction organization | 27/2897 | 80/18723 | 3.95e-05 | 1.00e-03 | 27 |
GO:01201921 | Colorectum | SER | tight junction assembly | 25/2897 | 74/18723 | 7.39e-05 | 1.66e-03 | 25 |
GO:00511681 | Colorectum | SER | nuclear export | 42/2897 | 154/18723 | 1.19e-04 | 2.46e-03 | 42 |
GO:00105061 | Colorectum | SER | regulation of autophagy | 74/2897 | 317/18723 | 1.39e-04 | 2.77e-03 | 74 |
GO:00342841 | Colorectum | SER | response to monosaccharide | 56/2897 | 225/18723 | 1.52e-04 | 2.98e-03 | 56 |
GO:00016491 | Colorectum | SER | osteoblast differentiation | 56/2897 | 229/18723 | 2.49e-04 | 4.21e-03 | 56 |
GO:00468251 | Colorectum | SER | regulation of protein export from nucleus | 13/2897 | 30/18723 | 2.52e-04 | 4.23e-03 | 13 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05012 | Colorectum | AD | Parkinson disease | 147/2092 | 266/8465 | 2.53e-27 | 8.48e-25 | 5.41e-25 | 147 |
hsa04714 | Colorectum | AD | Thermogenesis | 120/2092 | 232/8465 | 2.76e-19 | 1.16e-17 | 7.37e-18 | 120 |
hsa05020 | Colorectum | AD | Prion disease | 133/2092 | 273/8465 | 2.47e-18 | 8.29e-17 | 5.29e-17 | 133 |
hsa04530 | Colorectum | AD | Tight junction | 76/2092 | 169/8465 | 5.49e-09 | 9.69e-08 | 6.18e-08 | 76 |
hsa05110 | Colorectum | AD | Vibrio cholerae infection | 29/2092 | 50/8465 | 5.10e-07 | 7.12e-06 | 4.54e-06 | 29 |
hsa04919 | Colorectum | AD | Thyroid hormone signaling pathway | 51/2092 | 121/8465 | 1.71e-05 | 1.73e-04 | 1.10e-04 | 51 |
hsa04723 | Colorectum | AD | Retrograde endocannabinoid signaling | 59/2092 | 148/8465 | 2.94e-05 | 2.73e-04 | 1.74e-04 | 59 |
hsa04961 | Colorectum | AD | Endocrine and other factor-regulated calcium reabsorption | 24/2092 | 53/8465 | 8.49e-04 | 5.93e-03 | 3.78e-03 | 24 |
hsa04213 | Colorectum | AD | Longevity regulating pathway - multiple species | 27/2092 | 62/8465 | 8.72e-04 | 5.96e-03 | 3.80e-03 | 27 |
hsa04922 | Colorectum | AD | Glucagon signaling pathway | 41/2092 | 107/8465 | 1.18e-03 | 7.75e-03 | 4.94e-03 | 41 |
hsa05205 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
hsa05163 | Colorectum | AD | Human cytomegalovirus infection | 75/2092 | 225/8465 | 2.00e-03 | 1.10e-02 | 7.01e-03 | 75 |
hsa04912 | Colorectum | AD | GnRH signaling pathway | 35/2092 | 93/8465 | 3.69e-03 | 1.90e-02 | 1.21e-02 | 35 |
hsa04140 | Colorectum | AD | Autophagy - animal | 49/2092 | 141/8465 | 4.58e-03 | 2.20e-02 | 1.40e-02 | 49 |
hsa05166 | Colorectum | AD | Human T-cell leukemia virus 1 infection | 72/2092 | 222/8465 | 5.24e-03 | 2.44e-02 | 1.55e-02 | 72 |
hsa04962 | Colorectum | AD | Vasopressin-regulated water reabsorption | 19/2092 | 44/8465 | 5.48e-03 | 2.48e-02 | 1.58e-02 | 19 |
hsa04728 | Colorectum | AD | Dopaminergic synapse | 46/2092 | 132/8465 | 5.55e-03 | 2.48e-02 | 1.58e-02 | 46 |
hsa04211 | Colorectum | AD | Longevity regulating pathway | 33/2092 | 89/8465 | 6.15e-03 | 2.68e-02 | 1.71e-02 | 33 |
hsa04971 | Colorectum | AD | Gastric acid secretion | 29/2092 | 76/8465 | 6.25e-03 | 2.68e-02 | 1.71e-02 | 29 |
hsa04928 | Colorectum | AD | Parathyroid hormone synthesis, secretion and action | 38/2092 | 106/8465 | 6.60e-03 | 2.77e-02 | 1.76e-02 | 38 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRKACA | SNV | Missense_Mutation | | c.382N>C | p.Glu128Gln | p.E128Q | P17612 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
PRKACA | SNV | Missense_Mutation | | c.656N>T | p.Ala219Val | p.A219V | P17612 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
PRKACA | SNV | Missense_Mutation | | c.248T>C | p.Leu83Pro | p.L83P | P17612 | protein_coding | deleterious(0) | probably_damaging(0.925) | TCGA-E2-A15L-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
PRKACA | SNV | Missense_Mutation | | c.589N>A | p.Trp197Arg | p.W197R | P17612 | protein_coding | deleterious(0) | probably_damaging(0.91) | TCGA-E2-A1IU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
PRKACA | SNV | Missense_Mutation | | c.376N>A | p.Gly126Ser | p.G126S | P17612 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-GM-A2DO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | CR |
PRKACA | deletion | Frame_Shift_Del | novel | c.871delN | p.Asp291IlefsTer99 | p.D291Ifs*99 | P17612 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PRKACA | SNV | Missense_Mutation | | c.710C>T | p.Pro237Leu | p.P237L | P17612 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-C5-A7CH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | | SD |
PRKACA | SNV | Missense_Mutation | | c.450G>T | p.Gln150His | p.Q150H | P17612 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PRKACA | SNV | Missense_Mutation | | c.700N>A | p.Ala234Thr | p.A234T | P17612 | protein_coding | deleterious(0.04) | possibly_damaging(0.567) | TCGA-CK-5913-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PRKACA | SNV | Missense_Mutation | | c.442N>A | p.Ala148Thr | p.A148T | P17612 | protein_coding | deleterious(0.02) | probably_damaging(0.951) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5566 | PRKACA | SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE | | ALISERTIB | ALISERTIB | |
5566 | PRKACA | SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE | | TCMDC-125758 | CHEMBL546797 | |
5566 | PRKACA | SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE | | CYC-116 | CYC-116 | |
5566 | PRKACA | SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE | | AG-1879 | CHEMBL406845 | |
5566 | PRKACA | SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE | | CENISERTIB | CENISERTIB | |
5566 | PRKACA | SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE | | GO-6976 | GO-6976 | |
5566 | PRKACA | SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE | inhibitor | CHEMBL494089 | GSK-690693 | |
5566 | PRKACA | SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE | | PD-0166285 | PD-0166285 | |
5566 | PRKACA | SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE | inhibitor | 178102606 | CHEMBL104264 | |
5566 | PRKACA | SERINE THREONINE KINASE, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, ENZYME, CLINICALLY ACTIONABLE | | FASUDIL | FASUDIL | |